Amplify Transformational Data Sharing ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $61.05, while Regeneron Pharmaceuticals Inc trades at $663.85 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Amplify Transformational Data Sharing ETF pays none. Which is the better fit depends on your goals.
| BLOK | REGN | |
|---|---|---|
52-Week High | $74.10 | $812.27 |
52-Week Low | $47.36 | $542.52 |
Market Cap | — | $68.79B |
Sector | — | Health |
Enterprise Value | — | $62.74B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.81, down 2.95% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights the fund's diversified blockchain economy exposure, including bitcoin miners and enterprise adopters. The company announced a $0.08 dividend scheduled for June 2026, providing income potential for shareholders.
Outlook remains cautious with technical indicators signaling bearish momentum. The fund's increased bitcoin exposure to approximately 40% introduces volatility risks, though diversification across AI infrastructure and payment processors offers some stability. Investment opportunity exists for long-term investors seeking blockchain economy exposure, but near-term performance depends heavily on crypto market direction and AI infrastructure growth.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Trailing returns across standard periods
Latest headlines on both assets
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →